Treatment with HIV-1 protease inhibitors (PI) is associated with a reduced incidence or regression of Kaposi sarcoma (KS). Here we show that systemic administration of the PIs indinavir or saquinavir to nude mice blocks the development and induces regression of angioproliferative KS-like lesions promoted by primary human KS cells, basic fibroblast growth factor (bFGF), or bFGF and vascular endothelial growth factor (VEGF) combined. These PIs also block bFGF or VEGF-induced angiogenesis in the chorioallantoic membrane assay with a potency similar to paclitaxel (Taxol). These effects are mediated by the inhibition of endothelial- and KS-cell invasion and of matrix metalloproteinase-2 proteolytic activation by PIs at concentrations present in plasma of treated individuals. As PIs also inhibit the in vivo growth and invasion of an angiogenic tumor-cell line, these data indicate that PIs are potent anti-angiogenic and anti-tumor molecules that might be used in treating non-HIV KS and in other HIV-associated tumors.

Sgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S., et al. (2002). HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. NATURE MEDICINE, 8(3), 225-232 [10.1038/nm0302-225].

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

BARILLARI, GIOVANNI;
2002-03-01

Abstract

Treatment with HIV-1 protease inhibitors (PI) is associated with a reduced incidence or regression of Kaposi sarcoma (KS). Here we show that systemic administration of the PIs indinavir or saquinavir to nude mice blocks the development and induces regression of angioproliferative KS-like lesions promoted by primary human KS cells, basic fibroblast growth factor (bFGF), or bFGF and vascular endothelial growth factor (VEGF) combined. These PIs also block bFGF or VEGF-induced angiogenesis in the chorioallantoic membrane assay with a potency similar to paclitaxel (Taxol). These effects are mediated by the inhibition of endothelial- and KS-cell invasion and of matrix metalloproteinase-2 proteolytic activation by PIs at concentrations present in plasma of treated individuals. As PIs also inhibit the in vivo growth and invasion of an angiogenic tumor-cell line, these data indicate that PIs are potent anti-angiogenic and anti-tumor molecules that might be used in treating non-HIV KS and in other HIV-associated tumors.
mar-2002
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/05 - PATOLOGIA CLINICA
English
Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Endothelial Growth Factors; Endothelium, Vascular; Extraembryonic Membranes; Female; Fibroblast Growth Factor 2; HIV Protease Inhibitors; Humans; Indinavir; Lymphokines; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Saquinavir; Sarcoma, Kaposi; Skin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors
Sgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S., et al. (2002). HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. NATURE MEDICINE, 8(3), 225-232 [10.1038/nm0302-225].
Sgadari, C; Barillari, G; Toschi, E; Carlei, D; Bacigalupo, I; Baccarini, S; Palladino, C; Leone, P; Bugarini, R; Malavasi, L; Cafaro, A; Falchi, M; Valdembri, D; Rezza, G; Bussolino, F; Monini, P; Ensoli, B
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/188447
Citazioni
  • ???jsp.display-item.citation.pmc??? 74
  • Scopus 289
  • ???jsp.display-item.citation.isi??? ND
social impact